{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-029715","form_type":"8-K","ticker":"SONM","cik":"0001178697","company_name":"DNA X, Inc.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.837555+00:00","generated_at":"2026-06-22T23:39:44.754831+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sonim shareholders approve 5M share increase to equity plan and authorize reverse stock split","bullets":["Amendment to 2019 Equity Incentive Plan adding 5,000,000 shares approved by shareholders (21.6M For, 1.1M Against).","Reverse stock split authorized at ratio between 2:1 and 15:1, with exact ratio determined by board (26.3M For, 1.4M Against).","All seven director nominees elected: Mulica, Howe, Wang, Steenstra, Cassano, Liu, Principe.","Moss Adams ratified as independent auditor for FY2022 (27.0M For, 0.6M Against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-029715","json":"https://secwatch.observer/filing/0001493152-22-029715.json","markdown":"https://secwatch.observer/filing/0001493152-22-029715.md","text":"https://secwatch.observer/filing/0001493152-22-029715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178697/000149315222029715/0001493152-22-029715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178697/000149315222029715/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:39:44.754831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27f8eb8c3a5e0519dbe03a02b55d9c23bfe0f506","claim":"DNA X, Inc. shareholders approved Amendment to Plan to increase authorized shares by 5,000,000 at the 2022-10-26 meeting.","evidence_excerpt":"Proposal 2 : The stockholders approved an amendment to the Plan to increase the aggregate number of shares of common stock authorized for issuance by 5,000,000 shares, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 21,578,652 1,104,564 20,891 4,961,564","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315222029715/0001493152-22-029715-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-10-26"}],"fact_type":"shareholder_vote"},{"claim_id":"30ac810b382e18ff123e046d21b5df6ba22b20c4","claim":"DNA X, Inc. shareholders approved Amendment to Certificate of Incorporation to effect reverse stock split at the 2022-10-26 meeting.","evidence_excerpt":"Proposal 3 : A proposal to amend the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s common stock, pursuant to which any whole number of outstanding shares between and including two (2) and fifteen (15) shares would be combined, converted and changed into one (1) share of common stock, with the final exchange ratio to be determined by the Company’s board of directors in its discretion, was approved as set forth below: Votes For Votes Against Votes Abstained Broker Non-Votes 26,257,914 1,368,772 38,985 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315222029715/0001493152-22-029715-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-10-26"}],"fact_type":"shareholder_vote"},{"claim_id":"ae3080452cdb0a20ec35a6fcc047fbc0e1f8ddf5","claim":"DNA X, Inc. shareholders approved Ratification of Moss Adams as independent registered public accounting firm at the 2022-10-26 meeting.","evidence_excerpt":"Proposal 4 : The stockholders, on an advisory basis, ratified the appointment of Moss Adams as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 26,955,843 613,682 96,146 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315222029715/0001493152-22-029715-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-10-26"}],"fact_type":"shareholder_vote"},{"claim_id":"c25c0174a28b5184257aa6a8bc32f143ef76581b","claim":"DNA X, Inc. shareholders approved Election of seven director nominees at the 2022-10-26 meeting.","evidence_excerpt":"Proposal 1 : The stockholders elected each of the seven director nominees to the Board of Directors of the Company to serve until the next annual meeting and until his or her successor has been duly elected and qualified, as follows: Name Votes For Votes Withheld Broker Non-Votes Mike Mulica 21,968,984 735,123 4,961,564 Alan Howe 22,119,741 584,366 4,961,564 Jeffrey Wang 22,150,044 554,063 4,961,564 Jack Steenstra 22,137,165 566,942 4,961,564 James Cassano 22,137,566 566,541 4,961,564 Peter Liu 22,147,770 556,337 4,961,564 Jose C. Principe 22,137,147 566,960 4,961,564","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315222029715/0001493152-22-029715-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-10-26"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}